Page last updated: 2024-09-05

erlotinib hydrochloride and Disease Exacerbation

erlotinib hydrochloride has been researched along with Disease Exacerbation in 243 studies

Research

Studies (243)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	47 (19.34)	29.6817
2010's	180 (74.07)	24.3611
2020's	16 (6.58)	2.80

Authors

Authors	Studies
Ieda, M; Nagashio, K; Sato, K; Tajiri, K	1
Endo, M; Harada, H; Kenmotsu, H; Ko, R; Kobayashi, H; Kodama, H; Mamesaya, N; Miyawaki, E; Miyawaki, T; Mori, K; Murakami, H; Naito, T; Nishioka, N; Omori, S; Ono, A; Takahashi, K; Takahashi, T; Wakuda, K	1
Azuma, K; Haratake, N; Hayashi, H; Nakagawa, K; Nakano, Y; Oki, M; Ota, K; Sakamoto, T; Seto, T; Shimokawa, M; Yamamoto, N; Yoshioka, H	1
Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC	1
Bonanno, L; Buoro, V; Calabrese, F; Cecere, FL; Conte, P; Dal Maso, A; Del Conte, A; Frega, S; Indraccolo, S; Lorenzi, M; Macerelli, M; Monteverdi, S; Nardo, G; Pasello, G; Pilotto, S; Polo, V; Roca, E; Scattolin, D; Urso, L; Zulato, E	1
Chen, CY; Chen, YF; Chen, YH; Shih, JY; Yu, CJ	1
Chella, A; Crucitta, S; Danesi, R; Del Re, M; Garassino, MC; Gianfilippo, G; Mazzoni, F; Miccoli, M; Petrini, I; Pozzessere, D; Restante, G; Rofi, E; Valleggi, S	1
Bilici, A; Dagel, T; Dilege, S; Ertuglu, LA; Erus, S; Kanbay, M; Kapdağlı, M; Mandel, NM; Ozdogan, E; Selcukbiricik, F; Tanju, S; Tural, D	1
Grubbs, CJ; Juliana, MM; Lubet, RA; Miller, MS; Moeinpour, FL; Mohammed, A; Sei, S; Shoemaker, RH; Suen, CS	1
Bodemer, C; Boucheix, C; Chaumon, S; Doz, F; Greco, C; Hadj-Rabia, S; Leclerc-Mercier, S; Molina, T	1
Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R	1
Chen, J; Li, X; Liu, H; Liu, M; Zhang, H	1
Miyazaki, K; Okauchi, S; Satoh, H; Yamada, H	1
Bian, H; Birnbaumer, L; Dai, B; Feng, J; Guo, H; Hossain, MA; Hu, W; Li, L; Liu, G; Ni, J; Shen, Y; Shi, Y; Tian, Z; Wang, D; Wu, M; Yang, H; Yang, Y; Yu, D; Yu, J; Zhang, Q; Zheng, S	1
Cao, MQ; Lei, M; Li, KS; Li, XL; Liu, HD; Liu, XF; Shi, WK; Sun, HC; Tang, ZY; Xiao, N; Xu, B; Xu, YF; Zhang, SZ; Zhang, YY; Zhu, XD	1
Govindan, R; Larson, S; Lockhart, AC; Luo, J; Morgensztern, D; Park, H; Suresh, R; Tan, B; Trikalinos, NA; Van Tine, BA; Wang-Gillam, A; Waqar, S; Williams, K	1
Chen, C; Lin, H; Mei, Q; Ye, L	1
Baty, F; Brutsche, M; Früh, M; Joerger, M; Klingbiel, D; Zappa, F	1
Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X	1
Davies, L; Fukuoka, M; Gebski, V; Gralla, RJ; Inoue, A; Lee, CK; Lord, S; Marschner, I; Mitsudomi, T; Mok, T; Nakagawa, K; Rosell, R; Thongprasert, S; Tu, YK; Wu, YL; Yang, JC; Zhou, C	1
He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX	1
Abraham, E; Albright, C; Alistar, AT; Bitting, RL; Blackstock, W; Chen, K; D'Agostino, RB; Desnoyers, RJ; DeYoung, B; Foley, KL; Goodman, M; Grant, SC; Kytola, V; Levine, EA; Nykter, M; Pagni, M; Pasche, B; Petro, RM; Petty, WJ; Porosnicu, M; Powell, BL; Qasem, SA; Robinson, M; Staren, ED; Thomas, A; Topaloglu, U; Vatca, M; Yang, M; Zhang, W	1
Bartom, E; Bi, Y; Burant, CF; Calvert, AE; Chalastanis, A; Chandel, NS; Davuluri, RV; Dubrovskyi, O; Horbinski, C; Hua, Y; Hurley, LA; James, CD; Kachman, M; Kouri, FM; May, JL; Mazar, AP; Mishra, RK; Peter, ME; Schiltz, GE; Stegh, AH; Wu, Y; Zheng, H	1
Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T	1
Archila, P; Arrieta, O; Cardona, AF; Carranza, H; Corrales, L; Cuello, M; Karachaliou, N; Martín, C; Ortiz, C; Otero, J; Pino, LE; Reguart, N; Rojas, L; Rosell, R; Vargas, C; Wills, B; Zapata, MI; Zatarain-Barrón, ZL	1
Foster, A; Patel, SH; Riely, GJ; Rimner, A; Woo, KM; Wu, AJ; Yu, HA; Zhang, Z	1
Boland, P; Chhatrala, R; Fountzilas, C; Hutson, A; Iyer, R; Khushalani, N; LeVea, C; Ma, WW; Tan, W; Tucker, C; Warren, G	1
Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M	1
Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L	1
Bahra, M; Bechstein, W; Bischoff, S; Dörken, B; Gellert, K; Ghadimi, M; Grützmann, R; Jacobasch, L; Liersch, T; Maschmeyer, G; Messmann, H; Oettle, H; Pelzer, U; Rau, BM; Riess, H; Sinn, M; Stieler, JM; Striefler, JK; Waldschmidt, D; Weinmann, A; Wilhelm, M	1
Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J	1
Broniscer, A; Cooper, DA; Hwang, S; Li, X; Li, Y; Lucas, JT; Merchant, TE; Orr, B; Tinkle, C	1
Beccaria, K; Blauwblomme, T; Boddaert, N; Bolle, S; Brunelle, F; Calmon, R; Castel, D; Dhermain, F; Dufour, C; Grevent, D; Grill, J; Puget, S; Sainte-Rose, C; Saitovitch, A; Varlet, P; Zilbovicius, M	1
Fukuda-Hihara, K; Iseri, K; Iyoda, M; Matsumoto, K; Saito, T; Shibata, T; Suzuki, T; Tachibana, S; Wada, Y; Yamamoto, Y	1
Costa, JC; Grauslund, M; Melchior, LC; Santoni-Rugiu, E; Sørensen, JB; Urbanska, EM	1
Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B	1
Akerley, W; Chalmers, A; Jensen, L	1
Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM	1
Bosch-Barrera, J; Guerra Prió, S; Hernández Martínez, A; Izquierdo Font, A; López Brunsó, M; Mas Pueyo, HG; Roa García, D; Sais Girona, E; Toro Blanch, C	1
Demuth, C; Madsen, AT; Meldgaard, P; Sorensen, BS; Weber, B; Wu, L	1
Glisson, BS; Gold, KA; Johnson, FM; Kies, MS; Lee, JJ; William, WN	1
Baglivo, S; Brambilla, M; Chiari, R; Ludovini, V; Maiettini, D; Metro, G; Rebonato, A; Reda, MS; Ricciuti, B; Sidoni, A; Siggillino, A	1
Akerley, W; Barlesi, F; Blackler, AR; Buttigliero, C; Favaretto, AG; Hirsh, V; Novello, S; Orlov, S; Ramlau, R; Roder, J; Santoro, A; Scagliotti, GV; Schwartz, B; Shepherd, FA; Spigel, D	1
Hove, J; Powell, SF; Wynja, E	1
Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH	1
Aguiar-Bujanda, D; Blanco-Sanchez, MJ; Bohn-Sarmiento, U; Dueñas-Comino, A; Galvan-Ruiz, S; Hernandez-Sosa, M; Lorenzo-Barreto, JE; Mori-De Santiago, M; Ros-Sanjuan, L; Saura-Grau, S; Vargas-Prado, AM	1
Chen, JS; Chen, KY; Ho, CC; Hsu, CL; Lee, JH; Liao, WY; Lin, YT; Lin, ZZ; Shih, JY; Yang, CY; Yang, JC; Yu, CJ	1
Agazzi, GM; Berruti, A; Bettoni, V; Borghesi, A; Caprioli, A; Farina, D; Ganeshan, B; Maroldi, R; Ravanelli, M; Roca, E; Tononcelli, E	1
Ali, SM; Atkinson, EC; Chachoua, A; Nelson, AW; Pavlick, DC; Schrock, AB	1
Fujii, K; Ichiyasu, H; Ikeda, T; Imamura, K; Kashiwabara, K; Komatu, T; Maruyama, H; Saeki, S; Sakagami, T; Saruwatari, K; Shingu, N; Tomita, Y; Ushijima, S	1
Erikson, AK; Paripati, HR; Sheedy, JT; Shoudis, SN; Sio, TT; Yu, NY	1
Aguiar-Bujanda, D; Artal-Cortes, Á; DE Castro, J; Fírvida, JL; Fuentes, JC; Galán, R; Gordo, R; Oramas, J; Ortega-Granados, AL; Trigo, J	1
Baretta, Z; Basso, M; Bernardi, D; Bonanno, L; Bonetti, A; Bortolami, A; Calvetti, L; Conte, P; Corte, DD; Favaretto, A; Frega, S; Gatti, C; Giovanis, P; Gori, S; Guarneri, V; Menis, J; Oliani, C; Oniga, F; Palazzolo, G; Pasello, G; Redelotti, R; Rosetti, F; Santo, A; Toso, S; Vicario, G; Zustovich, F	1
Endo, M; Gon, Y; Harada, H; Kawamura, T; Kenmotsu, H; Kobayashi, H; Mamesaya, N; Mitsuya, K; Miyawaki, E; Mori, K; Murakami, H; Naito, T; Nakashima, K; Nakasu, Y; Omori, S; Ono, A; Takahashi, T; Wakuda, K	1
Borghaei, H; Camidge, R; Deal, A; Kavanagh, B; Kirpalani, P; Lee, C; Morris, D; Pecot, CV; Pennell, N; Stevenson, J; Stinchcombe, T; Villaruz, L; Weiss, J; West, J; Zagar, T	1
Ding, JY; Gao, J; Jiang, JH; Jin, C; Li, HR	1
Asai, G; Azuma, K; Fujita, Y; Fukuhara, T; Furuya, N; Gemma, A; Hagiwara, K; Iwasawa, S; Kobayashi, K; Kurimoto, F; Maemondo, M; Miyazaki, M; Morita, S; Nagashima, H; Nakachi, I; Nukiwa, T; Okada, M; Saito, H; Sugawara, S; Tsubata, Y; Tsunezuka, Y; Watanabe, K; Watanabe, S; Yamaguchi, O; Yoshimori, K	1
Juhász, E; Kim, JH; Klingelschmitt, G; Walzer, S	1
Belaid, I; Ben Ayed, F; Debbiche, G; Jlassi, H; Rais, H	1
Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A	1
Chen, M; Dominguez, SL; Eastham-Anderson, J; Le Pichon, CE; Lewin-Koh, N; Ngu, H; Scearce-Levie, K; Solanoy, H; Watts, R	1
Agelaki, S; Agelidou, M; Christofillakis, C; Georgoulias, V; Giassas, S; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Rapti, A; Samonis, G; Souglakos, J; Vamvakas, L; Voutsina, A	1
Hsu, JH; Li, MF; Shiau, EL; Wu, MT	1
Cardarella, S; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Rabin, MS; Ramaiya, NH	1
Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N	1
Altug, S; Digumarti, R; Han, B; Kim, HK; Kim, SW; Lee, DH; Lee, JS; Orlando, M; Rodrigues-Pereira, J; Sahoo, TP; Song, XQ; Wang, J; Wang, X	1
Bichsel, KJ; Forney, E; Gogia, N; Hammiller, B; Hansen, LA; Malouff, T; Pena, Z; Watson, P	1
Bria, E; Cognetti, F; Gamucci, T; Gelibter, A; Mansueto, G; Milella, M; Moscetti, L; Ruggeri, EM; Sperduti, I; Vaccaro, V	1
Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, W; Hurwitz, SJ; Khuri, FR; Kono, SA; Lewis, M; Moore, CE; Moreno-Williams, R; Müller, S; Nannapaneni, S; Owonikoko, TK; Ramalingam, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Yang, CS; Zhao, Y	1
Baudrin, L; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Herman, D; Lavolé, A; Mennecier, B; Milleron, B; Molinier, O; Moreau, L; Morin, F; Moro-Sibilot, D; Pichon, E; Poudenx, M; Quoix, E; Sennelart, H; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G	1
Akinaga, S; Fujisaka, Y; Hayashi, H; Hirashima, T; Miyoshi, K; Murakami, H; Nakagawa, K; Satouchi, M; Takahashi, T; Takeda, K; Yamamoto, N	1
Dobrowsky, RT; Pan, P	1
Alfieri, RR; Ardizzoni, A; Bartolotti, M; Bordonaro, R; Bortesi, B; Bruzzi, P; Caffarra, C; Cavazzoni, A; Cosentino, S; Fumarola, C; Ippolito, M; Latteri, F; Petronini, PG; Ruffini, L; Scarlattei, M; Soto Parra, HJ; Spadaro, P; Tiseo, M	1
Bass, SA; Gibson, AM; Khurana Hershey, GK; Xiao, C; Zhang, Z	1
Baio, G	1
Afonso-Afonso, FJ; Alonso-Jáudenes, G; Amenedo, M; Barón-Duarte, FJ; Campos-Balea, B; Casal Rubio, J; Fírvida-Pérez, JL; Huidobro, G; Lázaro-Quintela, M; López-Vázquez, MD; Santomé, L; Vázquez, S	1
Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H	1
Antoine, M; Cadranel, J; Duruisseaux, M; Lacave, R; Lavole, A; Leprieur, EG; Rabbe, N; Rozensztajn, N; Ruppert, AM; Vieira, T; Wislez, M	1
Heideman, DA; Kuiper, JL; Postmus, PE; Smit, EF; Thunnissen, E; van Wijk, AW	1
Carcereny, E; Cardenal, F; Cardona, AF; De Castro, J; Insa, A; Isla, D; Majem, M; Molina, MA; Moran, T; Pallarès, MC; Palmero, R; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Taron, M	1
Bardeesy, N; Caravan, P; Chen, X; Crenshaw, A; DePeralta, DK; Fuchs, BC; Fujii, T; Golub, TR; Gupta, S; Hoshida, Y; Kuroda, T; Lanuti, M; Lauwers, GY; McGinn, CM; Onofrio, R; Schmitt, AD; Tanabe, KK; Taylor, B; Wei, L; Winckler, W; Yamada, S	1
Beal, K; Chan, TA; Gerber, NK; Riely, GJ; Rimner, A; Shi, W; Wu, AJ; Yamada, Y; Yu, HA; Zhang, Z	1
Chen, X; Fan, L; Fei, K; Gao, G; He, Y; Li, A; Li, J; Li, S; Li, W; Li, X; Ren, S; Schmid-Bindert, G; Shi, J; Zhao, C; Zhou, C	1
Harris, RC; Paueksakon, P; Wang, Y; Zhang, MZ	1
Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S	1
Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A	1
Garzon, F; Geater, SL; Gopalakrishna, P; Iannotti, N; Lee, V; Lim, WT; Mok, TS; Reyderman, L; Reynolds, C; Smith, D; Spira, A; Thongprasert, S; Wang, B; Xu, L	1
Ardizzoni, A; Cappuzzo, F; Cortinovis, D; de Marinis, F; Fontanini, G; Galetta, D; Gridelli, C; Grossi, F; Iurlaro, M; Lorusso, V; Novello, S; Santo, A	1
Baty, F; Betticher, DC; Brauchli, P; Brutsche, M; Droege, C; Früh, M; Gautschi, O; Joerger, M; Klingbiel, D; Ochsenbein, A; Pless, M; Rothschild, S; Stahel, RA; von Moos, R; Zappa, F	1
Chen, YM; Chiu, CH; Lai, SL; Lee, YC; Shih, JF; Wu, CH; Wu, WS	1
Meldgaard, P; Nissen, PH; Sorensen, BS; Weber, B; Winther Larsen, A	1
Meldgaard, P; Nexo, E; Sorensen, BS; Tsai, J; Weber, B; Wei, W; Wu, L	1
Ge, N; Jiao, W; Qiu, T; Shen, Y; Tang, D; Wang, Y; Xuan, Y; Yan, G; Yao, R	1
Abdulrahman, R; Ahn, C; Bunn, PA; Camidge, DR; Choy, H; Doebele, RC; Dowell, J; Gaspar, LE; Gerber, DE; Hughes, R; Iyengar, P; Kavanagh, BD; Smith, I; Timmerman, R; Wardak, Z	1
Becker, A; Heideman, DA; Kuiper, JL; Ronden, MI; Smit, EF; Thunnissen, E; van Hengel, P; Ylstra, B	1
Costa, DB; Desai, NV; Folch, E; Gangadharan, SP; Huberman, MS; Karp, RS; Kent, MS; Le, X; Majid, A; Rangachari, D; VanderLaan, PA	1
Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA	1
Acker, T; Andreas, S; Fischer, J; Grah, C; Kollmeier, J; Kortsik, C; Müller, E; Penzel, R; Reinmuth, N; Reuss, A; Schenk, M; Schnabel, P; Schröder, M; Serke, M; Thomas, M; Villalobos, M; von Eiff, M; Witt, C; Wolf, M	1
Hart, EM; Johnson, ML; Kris, MG; Patel, JD; Rademaker, AW; Riely, GJ; Weitner, BB; Yu, HA	1
Dahlberg, SE; Jackman, DM; Jänne, PA; Johnson, BE; Lo, PC; Nishino, M; Oxnard, GR; Sequist, LV	1
Bonetti, A; Giuliani, J; Martelli, S; Remo, A	1
Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II	1
Anderson, R; Berns, EM; Boeckx, B; Casado, A; Coens, C; Despierre, E; Ferrero, A; Hirsch, FR; Jimeno, A; Katsaros, D; Lambrechts, D; Ray-Coquard, I; Varella-Garcia, M; Vergote, I	1
Hwang, IG; Jang, JS; Kang, JH; Kang, MH; Kim, CK; Kim, HG; Kim, HJ; Kim, SH; Lee, J; Lee, S; Oh, SY; Park, K; Park, MJ; Park, YS; Son, C; Song, KH; Sun, JM; Yi, SY	1
Azuma, K; Hirai, K; Inokoshi, Y; Ishida, T; Ishii, T; Kanazawa, K; Katsuura, Y; Minemura, H; Munakata, M; Oishi, A; Oshima, K; Sekine, S; Tanino, Y; Yokouchi, H	1
Bothwell, KD; Hershberger, PA; Johnson, CS; Kuriakose, MA; Merzianu, M; Seshadri, M; Shaurova, T; Suresh, A	1
Guckenberger, M	1
Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M	1
Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N	1
Aono, H; Azuma, K; Hosomi, Y; Kato, T; Komase, Y; Kunitoh, H; Morita, S; Nakahara, Y; Nishikawa, M; Oba, MS; Okamoto, H; Okuma, Y; Sato, A; Takeoka, H; Watanabe, K; Yamada, K	1
Bover, I; Carcereny, E; Cardenal, F; Corre, R; de Aguirre, I; de Marinis, F; Drozdowskyj, A; Felip, E; Garcia-Gomez, R; Gervais, R; Insa, A; Isla, D; Jordana-Ariza, N; Karachaliou, N; Massuti, B; Mayo-de las Casas, C; Melloni, B; Molina-Vila, MA; Morales-Espinosa, D; Moran, T; Paz-Ares, L; Ponce-Aix, S; Porta, R; Queralt, C; Ramirez-Serrano, JL; Reguart, N; Rosell, R; Sánchez, JM; Vergnenegre, A; Viteri, S	1
Chikamori, K; Goto, K; Hida, T; Katakami, N; Maemondo, M; Nishio, M; Ohishi, N; Tamura, T	1
Abdel-Sattar, M; Sugay, A; Tien Ho, P; Ting, J; Wilson, L; Xiang, P	1
Arzt, J; Busman, TA; Holen, KD; Kirschbrown, W; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA	1
Kim, H; Kim, HS; Kwon, JW; Shin, S; Sohn, HS	1
Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C	1
Dahlberg, SE; Digumarthy, SR; Fulton, LE; Hatabu, H; Johnson, BE; Nishino, M; Sequist, LV	1
Cho-Phan, CD; Diehn, M; Myall, NJ; Neal, JW; Stehr, H; Wakelee, HA; Zhou, L; Zhou, LY	1
Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Reiser, B; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Sörgel, F; Steffens, M; Stelzer, C; Stingl, J; von Mallek, D	1
Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS	1
Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM	1
André, T; Artru, P; Bonnetain, F; Borbath, I; Bouché, O; Chibaudel, B; Glimelius, B; Goldstein, D; Hammel, P; Huguet, F; Louvet, C; Mineur, L; Shannon, J; van Laethem, JL	1
Atagi, S; Goto, K; Inagaki, N; Seto, T; Tajima, K; Tamura, T; Yamamoto, N	1
Boucher, D; Costa, DB; Dahlberg, SE; Feeney, N; Jackman, DM; Jänne, PA; Johnson, BE; O'Connell, A; Oxnard, GR; Paweletz, CP; Redig, AJ; Taibi, M; Yanagita, M	1
Chadha, AS; Chatterjee, D; Clemons, M; Crane, CH; Das, P; Delclos, ME; Fleming, JB; George, G; Gunther, JR; Javle, MM; Katz, MH; Krishnan, S; Minsky, BD; Munsell, MF; Singh, PK; Skinner, HD; Varadhachary, GR; Wang, H; Wolff, RA	1
Boucher, D; Costa, DB; Jackman, DM; Jänne, PA; Johnson, BE; Redig, AJ; Taibi, M	1
Anandharaj, A; Hong, KH; Kassie, F; Kim, JH; Kirtane, AR; Panyam, J; Song, JM; Upadhyaya, P	1
Berry, G; Burt, BM; Engleman, E; Kheradmand, F; Lee, HS; Sugarbaker, DJ; Wang, DH; Wheeler, TM; Yoon, D	1
Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL	1
Demuth, C; Meldgaard, P; Sorensen, BS; Sorensen, SF; Weber, B	1
Asmat, A; Kumarakulasinghe, NB; Loy, EY; Pang, B; Soo, RA; Soon, YY; Syn, N; Zheng, H	1
Forgez, P; Galmiche, A; Liu, J; Paradis, V; Segal-Bendirdjian, E; Stadler, N; Wendum, D; Wu, Z	1
Cicènas, S; Geater, SL; Hooper, G; Hotko, Y; Mudie, N; Petrov, P; Wu, YL; Xia, F	1
Pi, C; Xu, CR; Zhang, YC; Zhou, Q	1
Fraser, A	1
Chen, Z'; Khuri, FR; Lee, JE; Shin, DM; Shin, HJ; Tighiouart, M; Yang, CS; Zhang, H; Zhang, X	1
Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Holmes, AJ; Jänne, PA; Kang, JH; Ki, CS; Kim, HT; Kim, SW; Lee, JS; Park, BB; Park, CK; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS	1
Baselga, J; Cedres, S; Felip, E; Foernzler, D; Gatzemeier, U; Heller, A; Klughammer, B; Maacke, H; Möcks, J; Parera, M; Peralta, S; Reck, M; Rojo, F; Sala, G; Saura, C	1
Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H	1
Arusell, R; Brown, PD; Buckner, JC; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Jenkins, RB; Kitange, G; Krishnan, S; Kugler, JW; Mischel, P; Morton, RF; Rowland, KM; Sarkaria, JN; Scheithauer, BW; Schiff, D; Uhm, JH; Wu, W; Yong, WH	1
Ren, SX; Yan, LH; Zhang, L; Zhou, CC; Zhou, SW	1
Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH	1
Davidson, CR; Hardie, WD; Ikegami, M; Korfhagen, TR; Le Cras, TD; Schmidt, SM; Whitsett, JA	1
Lin, CC; Yang, CH	1
Manegold, C	1
Dhruva, N; Socinski, MA	1
Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N	1
Ren, S; Tang, L; Yan, L; Zhang, J; Zhang, L; Zhou, C; Zhou, S	1
Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM	1
Bonnichon, A; Le Floch, H; Mairovitz, A; Margery, J; Rivière, F; Staub, E; Vaylet, F	1
Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B	1
Amann, JM; Brahmer, J; Carbone, DP; Gonzalez, A; Lee, JW; Roder, H; Schiller, JH	1
Billheimer, D; Carbone, DP; Chen, H; Dang, TP; Herbst, RS; Roder, H; Roder, J; Salmon, JS; Sandler, A; Tran, HT; Tsao, AS; Tsypin, M	1
Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA	1
Chang, J; Cho, BC; Choi, HJ; Kim, JH; Kim, SK; Lee, YJ; Moon, JW; Park, IK	1
Bergsland, EK; Dito, E; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Schillinger, B; Scott, J; Tempero, MA; Venook, AP	1
Butler, JS; Donahue, BR; Huang, Y; Olmez, I; Rubin, P; Xu, Y	1
Belani, CP; Owonikoko, TK; Ramalingam, SS	1
Liao, ML; Qin, SK; Sun, Y; Wu, YL; Zhou, CC	1
Hotta, K; Inoue, K; Kishino, D; Kiura, K; Okada, T; Suzuki, E; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H	1
Anthoney, A; Blatter, J; Dean, E; Hanauske, AR; Kletzl, H; Klingelschmitt, G; Melezinek, I; Ranson, M; Reck, M; Twelves, C	1
Dunn, EF; Harari, PM; Wheeler, DL	1
Brückl, WM; Ficker, JH; Wiest, GH	1
English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A	1
Cioffredi, LA; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Van den Abbeele, AD; Yap, JT; Yeap, BY	1
Barker, FG; Batchelor, TT; Halpin, C; Loeffler, JS; McKenna, MJ; Plotkin, SR	1
Cho, EK; Hong, J; Jung, SH; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ	1
Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E	1
Fujiwara, K; Kudo, K; Matsuo, K; Mizuta, M; Sato, T; Tsushima, M; Yonei, T	1
Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V	1
Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY	1
Alberts, DS; Baker, AF; Brewer, MA; Chambers, SK; Clouser, MC; Cohen, JL; Cui, H; Gordon, AN; Gordon, MS; Hatch, KD; Isaacs, JD; Janicek, MF; Nagle, RB; Roe, DJ; Wright, HM	1
Colucci, G; Galetta, D; Millaku, A; Pisconti, S; Rossi, A	1
Chang, DS; Di, YP; Li, HQ; Li, P; Liu, LY; Wang, J; Wang, JD; Wang, X; Wang, YJ; Wu, WZ; Xia, TY	1
Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B	1
Amler, LC; Charu, V; Fine, BM; Gitlitz, BJ; Hicks, RJ; Hughes, BG; Macfarlane, D; Mileshkin, L; Mitchell, PL; Pirzkall, A; Solomon, B; Yu, W	1
Chen, X; Guo, R; Shu, Y; Sun, J; Wang, T; Zhang, Z	1
Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Wislez, M	1
Heigener, DF; Horwood, K; Mali, P; Reck, M; van Zandwijk, N; Wu, YL	1
Kern, I; Kovac, V; Rajer, M; Smrdel, U; Vrankar, M; Zwitter, M	1
Abdiche, S; Bonnabau, H; Chouaïd, C; Cumin, I; Decroisette, Ch; Ejnaini, CN; Hureaux, J; Lombard, JN; Mazières, J; Monnet, I; Quéré, G; Vergnenègre, A	1
Ma, S; Xu, Y; Zhang, Y	1
Barlesi, F	1
Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ	1
Blanchet, B; Goldwasser, F; Mir, O	1
Chaft, JE; Kris, MG; Miller, VA; Oxnard, GR; Riely, GJ; Sima, CS	1
Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK	1
Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A	1
Guo, J; Liu, Y; Wang, Y; Wang, Z; Yang, J	1
Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH	1
Allen-Auerbach, MS; Benz, MR; Czernin, J; Figlin, R; Garon, EB; Herrmann, K; Phelps, ME; Reckamp, KL; Walter, F; Weber, WA	1
Appleyard, CB; Coppola, D; Cruz, ML; Isidro, AA; Pagán, B; Ren, Y; Wu, J	1
Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM	1
Endo, M; Harada, H; Inomata, M; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N	1
Barletta, G; Boldrini, L; Brianti, A; Cosso, M; Dal Bello, MG; Defferrari, C; Fontanini, G; Genova, C; Grossi, F; Murolo, C; Pronzato, P; Rijavec, E; Truini, M	1
Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A	1
Kawada, A; Nakagawa, K; Oiso, N; Okamoto, I; Takeda, M; Tsurutani, J	1
Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N	1
Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY	1
Ahn, JS; Ahn, MJ; Cho, SH; Choi, YL; Han, JH; Hwang, DW; Ji, JH; Lee, JY; Park, K; Park, LC; Park, S; Sun, JM	1
Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R	1
Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A	1
Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC	1
Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK	1
Betticher, D; Brauchli, P; Bubendorf, L; Crowe, S; Droege, C; Froesch, P; Gautschi, O; Hess, T; Mayer, M; Ochsenbein, A; Oppliger Leibundgut, E; Pless, M; Rauch, D; Ribi, K; Schmid, P; Stahel, R; von Moos, R; Zappa, F	1
Edelman, MJ; Mok, T; O'Byrne, K; Paz-Ares, L; Rittweger, K; Spigel, DR; Thurm, H; Yu, W	1
Aisner, DL; Bunn, PA; Burke, JM; Camidge, DR; Doebele, RC; Gan, G; Gaspar, LE; Kavanagh, BD; Lu, X; Scheier, B; Weickhardt, AJ	1
Gridelli, C; Maione, P; Rossi, A	1
Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X	1
Agarwala, SS; Hidalgo, M; Senzer, NN; Siu, LL; Soulieres, D; Vokes, EE	1
Perez-Soler, R	1
Berlin, JD; Lockhart, AC; Lockhart, C	1
Kris, MG; Miller, VA; Pao, W; Politi, KA; Riely, GJ; Somwar, R; Varmus, H; Zakowski, MF	1
Fehrenbacher, L; Herbst, RS; Hermann, R; Johnson, BE; Johnson, DH; Klein, P; Kris, MG; Li, X; Miller, VA; Prager, D; Ramies, D; Sandler, A; Tran, HT	1
Altundag, K; Altundag, O; Boruban, C; Silay, YS	1
Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA	1
Reck, M	1
Chen, E; Dancey, J; Hedley, D; Ho, J; Major, P; Moore, MJ; Nicklee, T; Oza, AM; Pond, GR; Siu, LL; Townsley, CA; Tsao, M	1
Pérol, M	1
Dubinett, SM; Elashoff, RM; Figlin, RA; Krysan, K; Milne, GL; Morrow, JD; Newman, RA; Reckamp, KL; Tucker, C	1
Allmer, C; Donehower, RC; Erlichman, C; Fitch, T; Kim, G; Mahoney, MR; Philip, PA; Picus, J; Pitot, HC; Thomas, J	1
Bell, DW; Haber, DA; Halmos, B; Holmes, AJ; Huberman, MS; Jackman, DM; Jänne, PA; Johnson, BE; Joshi, VA; Lindeman, N; Lynch, TJ; Meyerson, M; Rabin, MS; Sequist, LV; Yeap, BY	1
Azzoli, CG; Dunne, M; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Rizvi, NA; Venkatraman, E	1
Hughes, S; Meehan, L; Moore, S; Norton, A; O'Brien, M; Papadopoulos, P; Popat, S; Priest, K; Wilkins, A	1
Bekele, BN; Herbst, RS; Liu, DD; Massarelli, E; Ozburn, NC; Tang, X; Varella-Garcia, M; Wistuba, II; Xavier, AC	1
Costa, DB	1
Chang, J; Cho, BC; Choi, HJ; Im, CK; Kim, H; Kim, JH; Kim, SK; Kim, YJ; Park, JP; Park, MS; Shin, SJ; Sohn, JH	1
Davies, A; Gandara, D; Ho, C; Mack, P	1
Carrión, RP; Gracián, AC; Hernandez, PS	1
Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A	1
Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK	1
Ferretti, G; Labianca, R; Mandalà, M; Moro, C	1
Fregoni, V; Pavesi, L; Ponchio, L; Prada, GA; Sagrada, P; Zambelli, A	1
Albert, D; Axelrod, R; Botkin, D; Dowlati, A; Lilenbaum, R; Seigel, L; Thomas, S; Witt, K	1
Costa, DB; Kobayashi, S; Schumer, ST; Tenen, DG	1
Adam, P; Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Quinkler, M; Ritte, C; Ritter, C; Strasburger, C; Wortmann, S	1
Chin, TM; Chuah, KL; Lim, SW; Nga, ME; Seah, SB; Soo, RA; Soong, R; Wong, AS	1
Shih, JY; Wu, SG; Yang, PC; Yu, CJ	1
Hainsworth, JD; Lin, M; O'Neill, V; Spigel, DR	1
Bertalanffy, A; Dieckmann, K; Dietrich, W; Gelpi, E; Hainfellner, JA; Marosi, C; Prayer, D; Preusser, M; Rottenfusser, A; Widhalm, G	1
Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP	1

Reviews

22 review(s) available for erlotinib hydrochloride and Disease Exacerbation

Article	Year
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment	2020
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2017, Volume: 65, Issue:5 Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome	2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Journal of the National Cancer Institute, 2017, 06-01, Volume: 109, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Sequence Deletion	2017
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. Tumori, 2017, Jul-31, Volume: 103, Issue:4 Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines	2017
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients. Journal of cellular physiology, 2019, Volume: 234, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic	2019
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:10 Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Quinazolinones; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Signal Transduction	2019
[Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature]. Revue de pneumologie clinique, 2013, Volume: 69, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Disease Progression; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Quinazolines; Radiography; Spinal Cord Neoplasms	2013
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Journal of clinical pharmacy and therapeutics, 2015, Volume: 40, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking	2015
[Targeted therapy for locally advanced and/or metastatic bladder cancer]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18, Issue:7 Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms	2008
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. Targeted oncology, 2009, Volume: 4, Issue:1 Topics: Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome	2009
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer. Clinical lung cancer, 2008, Volume: 9 Suppl 3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A	2008
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines	2010
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome	2010
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?]. Pneumologie (Stuttgart, Germany), 2010, Volume: 64, Issue:12 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2010
Second-line treatment for non-small-cell lung cancer: one size does not fit all. Clinical lung cancer, 2010, Sep-01, Volume: 11, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids	2010
Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question. Cancer treatment reviews, 2010, Volume: 36 Suppl 3 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Vascular Endothelial Growth Factor A	2010
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:4 Pt 1 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines	2011
EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Radiation Tolerance	2011
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-15, Volume: 10, Issue:12 Pt 2 Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome	2004
The epidermal growth factor receptor as a target for colorectal cancer therapy. Seminars in oncology, 2005, Volume: 32, Issue:1 Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction	2005
Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. Clinical lung cancer, 2007, Volume: 8, Issue:7 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2007
Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer. Clinical lung cancer, 2007, Volume: 8, Issue:7 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Karnofsky Performance Status; Lung Neoplasms; Quinazolines; Treatment Outcome	2007

Trials

91 trial(s) available for erlotinib hydrochloride and Disease Exacerbation

Article	Year
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). Clinical lung cancer, 2022, Volume: 23, Issue:3 Topics: Acrylamides; Aniline Compounds; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Ramucirumab	2022
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185). Thoracic cancer, 2020, Volume: 11, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult	2020
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. Cancer chemotherapy and pharmacology, 2021, Volume: 87, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Phosphatidylinositol 3-Kinase; Sirolimus; Treatment Outcome	2021
Clinical trial evaluating efficacy and safety of pemetrexed based chemotherapy regimen versus ramucirumab plus erlotinib in Chinese patients with lung cancer: A preliminary investigation. Pakistan journal of pharmaceutical sciences, 2020, Volume: 33, Issue:5(Special) Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Progression-Free Survival; Ramucirumab; Time Factors	2020
A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms	2017
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-10, Volume: 35, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors; Treatment Outcome; Young Adult	2017
Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System? International journal of radiation oncology, biology, physics, 2017, 10-01, Volume: 99, Issue:2 Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Disease Progression; Erlotinib Hydrochloride; Glioma; Humans; Magnetic Resonance Imaging; Neuroimaging; Prognosis; Prospective Studies; Radiotherapy Dosage; Regression Analysis; Treatment Failure	2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 113 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines	2017
Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer, 2018, 05-15, Volume: 124, Issue:10 Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Skin Neoplasms	2018
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. The oncologist, 2019, Volume: 24, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proteomics; Pyrrolidinones; Quinolines; Reagent Kits, Diagnostic; Retrospective Studies; Young Adult	2019
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer treatment and research communications, 2019, Volume: 19 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Radiosurgery; Survival Rate	2019
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. The Lancet. Oncology, 2019, Volume: 20, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Signal Transduction; Time Factors	2019
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:6 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Outcome	2013
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer, 2013, Aug-01, Volume: 119, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines	2013
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-20, Volume: 31, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines	2013
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Proportional Hazards Models; Quinazolines	2013
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World journal of gastroenterology, 2013, Jul-28, Volume: 19, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Patient Selection; Proportional Hazards Models; Prospective Studies; Quinazolines; Time Factors; Treatment Outcome	2013
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Disease Progression; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pyrazoles; Quinazolines; Sulfonamides	2014
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. British journal of cancer, 2013, Nov-26, Volume: 109, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Disease Progression; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines	2013
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome	2014
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:3 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2014
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 84, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Treatment Outcome; Vorinostat	2014
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate	2014
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. Oncology research, 2013, Volume: 21, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome	2013
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Furans; Humans; Ketones; Lung Neoplasms; Male; Middle Aged; Quinazolines	2014
MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial. Clinical advances in hematology & oncology : H&O, 2014, Volume: 12, Issue:1 Suppl 1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Genes, erbB-1; Genes, ras; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins	2014
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer, 2014, Dec-15, Volume: 120, Issue:24 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2014
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Dec-01, Volume: 32, Issue:34 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Colorado; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Risk Factors; Texas; Time Factors; Treatment Outcome	2014
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer. The European respiratory journal, 2015, Volume: 46, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Treatment Outcome	2015
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-20, Volume: 33, Issue:15 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Chaperones; Mutation; Quinazolines; Resorcinols; Treatment Outcome	2015
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer, 2015, Aug-01, Volume: 121, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Retrospective Studies; Time-to-Treatment; Treatment Failure	2015
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. International journal of radiation oncology, biology, physics, 2015, Jun-01, Volume: 92, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors	2015
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Targeted oncology, 2015, Volume: 10, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Mutation; Organoplatinum Compounds; Ovarian Neoplasms; Protein Kinase Inhibitors; Protein Kinases	2015
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Disease Progression; Disease-Free Survival; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Ointments; Pancreatic Neoplasms; Protein Kinase Inhibitors; Republic of Korea; Treatment Outcome	2016
A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer. BMC research notes, 2015, Jun-05, Volume: 8 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Treatment Outcome	2015
[Oligoprogression]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2015, Volume: 191, Issue:5 Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Retreatment; Survival Rate; Treatment Failure	2015
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2015
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA oncology, 2015, Volume: 1, Issue:2 Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Chi-Square Distribution; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Risk Factors; Time Factors; Treatment Outcome	2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5 Topics: Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides	2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:3 Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines	2016
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung cancer (Amsterdam, Netherlands), 2016, Volume: 93 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Risk Factors; Sorafenib; Treatment Outcome	2016
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. Cancer imaging : the official publication of the International Cancer Imaging Society, 2016, Mar-16, Volume: 16 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult	2016
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA, 2016, May-03, Volume: 315, Issue:17 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms	2016
Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies. Future oncology (London, England), 2016, Volume: 12, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Outcome	2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-15, Volume: 22, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell-Free Nucleic Acids; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Prospective Studies; Protein Kinase Inhibitors	2016
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PloS one, 2016, Volume: 11, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiation Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Repressor Proteins; Treatment Outcome	2016
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. JAMA oncology, 2016, Sep-01, Volume: 2, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met	2016
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung cancer (Amsterdam, Netherlands), 2016, Volume: 102 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds	2016
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-15, Volume: 14, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Ethnicity; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Time Factors; Treatment Outcome	2008
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-15, Volume: 14, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Erlotinib Hydrochloride; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Treatment Outcome	2008
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Temozolomide; Treatment Outcome	2008
Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology (Carlton, Vic.), 2009, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Transforming Growth Factor alpha; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis	2010
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 69, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Precision Medicine; Predictive Value of Tests; Proteome; Quinazolines	2010
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2010
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:2 Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate	2010
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome	2010
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR. American journal of roentgenology, 2010, Volume: 195, Issue:3 Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome	2010
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. The Korean journal of internal medicine, 2010, Volume: 25, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2010
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome	2011
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Nov-01, Volume: 16, Issue:21 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Likelihood Functions; Ovarian Neoplasms; Platinum Compounds; Prognosis; Quinazolines; Treatment Outcome; Tumor Microenvironment; Up-Regulation; Vascular Endothelial Growth Factor A	2010
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. American journal of clinical oncology, 2012, Volume: 35, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate	2012
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Survival Analysis; Thymidine	2011
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Quinazolines	2011
Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial. Journal of biomedicine & biotechnology, 2011, Volume: 2011 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Demography; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Radiography; Radionuclide Imaging; Smoking; Time Factors; Treatment Outcome	2011
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP British journal of cancer, 2011, Oct-11, Volume: 105, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids	2011
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome	2012
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, Volume: 52, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2011
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology, 2012, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines	2012
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure	2012
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC Lung cancer (Amsterdam, Netherlands), 2012, Volume: 77, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome	2012
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Aug-20, Volume: 30, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines	2012
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). BMC cancer, 2012, Jul-20, Volume: 12 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids	2012
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung cancer (Amsterdam, Netherlands), 2012, Volume: 78, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; ras Proteins; Treatment Outcome	2012
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Po Clinical lung cancer, 2012, Volume: 13, Issue:6 Topics: Adult; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design; Survival Analysis	2012
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-oncology, 2013, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution	2013
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines	2004
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-01, Volume: 23, Issue:25 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Protein Kinase Inhibitors; Quinazolines; Survival Analysis	2005
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-01, Volume: 11, Issue:21 Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors	2005
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. Future oncology (London, England), 2006, Volume: 2, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival; Treatment Outcome; Up-Regulation	2006
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. British journal of cancer, 2006, Apr-24, Volume: 94, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Recurrence; Risk Factors; Signal Transduction; Survival Rate; Treatment Outcome	2006
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pyrazoles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Treatment Outcome	2006
Phase II study of erlotinib in patients with advanced biliary cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-01, Volume: 24, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis	2006
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer, 2006, Sep-01, Volume: 107, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2006
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-20, Volume: 25, Issue:18 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome	2007
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome	2008
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires	2008
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:6 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Routes; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Salvage Therapy; Treatment Outcome	2008
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer, 2008, Jun-15, Volume: 112, Issue:12 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Female; Humans; In Vitro Techniques; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis	2008
Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. Journal of neuro-oncology, 2008, Volume: 89, Issue:2 Topics: Adult; Aged; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention	2008
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast cancer research and treatment, 2009, Volume: 115, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Taxoids	2009

Other Studies

130 other study(ies) available for erlotinib hydrochloride and Disease Exacerbation

Article	Year
Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer. International heart journal, 2021, Sep-30, Volume: 62, Issue:5 Topics: Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Cardiomyopathies; Cardiotoxicity; Disease Progression; Dyspnea; Erlotinib Hydrochloride; Female; Follow-Up Studies; Heart Failure; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors	2021
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC cancer, 2021, Nov-19, Volume: 21, Issue:1 Topics: Acrylamides; Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Failure	2021
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. Thoracic cancer, 2022, Volume: 13, Issue:14 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies	2022
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical lung cancer, 2020, Volume: 21, Issue:1 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; France; Gefitinib; Humans; Liquid Biopsy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation	2020
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. BMC cancer, 2019, Oct-26, Volume: 19, Issue:1 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Sequence Deletion	2019
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clinical lung cancer, 2020, Volume: 21, Issue:3 Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell-Free Nucleic Acids; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Survival Rate	2020
Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer. Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:2 Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Uric Acid	2020
Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers. Cancer prevention research (Philadelphia, Pa.), 2020, Volume: 13, Issue:3 Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Naproxen; Neoplasm Recurrence, Local; Neoplasms, Experimental; Pulse Therapy, Drug; Rats; Time Factors; Time-to-Treatment; Urinary Bladder; Urinary Bladder Neoplasms	2020
Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations. JAMA dermatology, 2020, 02-01, Volume: 156, Issue:2 Topics: Adolescent; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Keratoderma, Palmoplantar; Male; Mutation; Protein Kinase Inhibitors; Syndrome; TRPV Cation Channels	2020
Response to a combination of erlotinib and bevacizumab therapy after immune checkpoint inhibitor. The clinical respiratory journal, 2020, Volume: 14, Issue:5 Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Adenosquamous; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Treatment Outcome	2020
PLAGL2-EGFR-HIF-1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity. Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:2 Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Mice; Middle Aged; Neoplasm Invasiveness; RNA-Binding Proteins; RNA-Seq; Signal Transduction; Transcription Factors; Tumor Hypoxia; Up-Regulation; Xenograft Model Antitumor Assays	2021
NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma. Cell death & disease, 2020, 05-07, Volume: 11, Issue:5 Topics: 5'-Nucleotidase; Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Protein Binding; Protein Stability; Survival Analysis; Up-Regulation	2020
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. Journal of translational medicine, 2017, 03-30, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Signal Transduction	2017
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC cancer, 2017, 04-04, Volume: 17, Issue:1 Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines	2017
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. Journal of hematology & oncology, 2017, 05-04, Volume: 10, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Clone Cells; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genes, erbB-1; Genes, Neoplasm; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Protein Kinase Inhibitors; Retrospective Studies; Sequence Analysis, DNA; Smoking	2017
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell reports, 2017, 05-30, Volume: 19, Issue:9 Topics: Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Histones; Isocitrate Dehydrogenase; Ketoglutaric Acids; Lipids; Methylation; Mice; Mice, SCID; Molecular Targeted Therapy; Mutation; NADP; Neoplastic Stem Cells; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Messenger	2017
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clinical lung cancer, 2017, Volume: 18, Issue:6 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome	2017
Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). Targeted oncology, 2017, Volume: 12, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Hispanic or Latino; Humans; Lung Neoplasms; Male; Middle Aged; Mutation	2017
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 108 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Survival Analysis; Treatment Failure; Treatment Outcome	2017
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:3 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy	2018
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression. PloS one, 2017, Volume: 12, Issue:8 Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins	2017
Multimodal Magnetic Resonance Imaging of Treatment-Induced Changes to Diffuse Infiltrating Pontine Gliomas in Children and Correlation to Patient Progression-Free Survival. International journal of radiation oncology, biology, physics, 2017, 10-01, Volume: 99, Issue:2 Topics: Adolescent; Antineoplastic Agents; Brain; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Contrast Media; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Sirolimus; Statistics, Nonparametric; Survival Analysis; Time Factors; Tumor Burden	2017
Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018, 04-01, Volume: 33, Issue:4 Topics: Animals; Cells, Cultured; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Fibrosis; Humans; Macrophages; Male; Nephrectomy; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction	2018
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 113 Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Exons; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Receptor, Fibroblast Growth Factor, Type 3	2017
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 114 Topics: Acrylamides; Aged; Aniline Compounds; Brain; Carcinoma, Non-Small-Cell Lung; Cerebrospinal Fluid; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors	2017
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. Future oncology (London, England), 2018, Volume: 14, Issue:15 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure	2018
Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer. Anti-cancer drugs, 2018, Volume: 29, Issue:4 Topics: Amiodarone; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Paralysis; Radiotherapy; Withholding Treatment	2018
The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. BMC cancer, 2018, 02-15, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alleles; Amino Acid Substitution; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell-Free Nucleic Acids; Cohort Studies; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Protein Kinase Inhibitors	2018
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. Lung cancer (Amsterdam, Netherlands), 2018, Volume: 120 Topics: Adenocarcinoma; Antineoplastic Agents; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Proto-Oncogene Proteins p21(ras); Remission Induction; Survival Analysis; Time Factors	2018
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue. Oncology (Williston Park, N.Y.), 2018, Oct-15, Volume: 32, Issue:10 Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; Cell-Free Nucleic Acids; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Piperazines; Polymorphism, Restriction Fragment Length	2018
Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors. Oncology research and treatment, 2018, Volume: 41, Issue:12 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis	2018
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. International journal of cancer, 2019, 06-01, Volume: 144, Issue:11 Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Sex Factors; Taiwan; Time Factors	2019
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs). European journal of radiology, 2018, Volume: 109 Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Retrospective Studies; Tomography, X-Ray Computed	2018
Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:2 Topics: Acrylamides; Adenocarcinoma; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Oncogene Fusion; Phosphoproteins; Proto-Oncogene Proteins c-met	2019
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases. Anticancer research, 2019, Volume: 39, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Treatment Outcome	2019
Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report. Practical radiation oncology, 2019, Volume: 9, Issue:3 Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Face; Female; Humans; Lung Neoplasms; Radiodermatitis; Skin; Treatment Outcome	2019
Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced Anticancer research, 2019, Volume: 39, Issue:3 Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors	2019
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for The oncologist, 2019, Volume: 24, Issue:6 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Critical Pathways; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Guideline Adherence; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Mutation; Practice Guidelines as Topic; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Treatment Failure	2019
Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. International journal of radiation oncology, biology, physics, 2019, 07-01, Volume: 104, Issue:3 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Cranial Irradiation; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Radiosurgery; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome	2019
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers? Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate	2013
EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS. PloS one, 2013, Volume: 8, Issue:4 Topics: Amyotrophic Lateral Sclerosis; Animals; Astrocytes; Biomarkers; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Longevity; Mice; Mice, Transgenic; Microglia; Motor Neurons; Neuromuscular Junction; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Spinal Cord; Staining and Labeling; Superoxide Dismutase; Superoxide Dismutase-1; Survival Analysis; Synapses; Time Factors	2013
Recurrent respiratory papillomatosis with lung involvement and malignant transformation. Thorax, 2014, Volume: 69, Issue:3 Topics: Bronchial Neoplasms; Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Contrast Media; Disease Progression; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Tomography, X-Ray Computed; Treatment Outcome	2014
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR. American journal of roentgenology, 2013, Volume: 201, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome	2013
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PloS one, 2013, Volume: 8, Issue:7 Topics: Alopecia; Animals; Antineoplastic Agents; Apoptosis; Cyclophosphamide; Disease Progression; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Hair Follicle; Humans; Mice; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53	2013
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer. The European respiratory journal, 2014, Volume: 43, Issue:1 Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Failure; Treatment Outcome	2014
Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy. Acta neuropathologica communications, 2013, Jul-17, Volume: 1 Topics: Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Progression; Down-Regulation; Erlotinib Hydrochloride; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Neural Conduction; Neuregulin-1; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sural Nerve	2013
EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis. Journal of immunology (Baltimore, Md. : 1950), 2014, Feb-01, Volume: 192, Issue:3 Topics: Administration, Cutaneous; Allergens; Animals; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL2; Dermatitis, Atopic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Interleukin-17; Interleukin-1beta; Interleukin-22; Interleukin-6; Interleukins; Keratinocytes; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Quinazolines; Recurrence; Signal Transduction; Skin; Specific Pathogen-Free Organisms; Th17 Cells	2014
Bayesian models for cost-effectiveness analysis in the presence of structural zero costs. Statistics in medicine, 2014, May-20, Volume: 33, Issue:11 Topics: Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Models, Economic; Multicenter Studies as Topic; Quality-Adjusted Life Years; Quinazolines	2014
[Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines	2013
Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors. Cancer medicine, 2014, Volume: 3, Issue:1 Topics: Aged; Aged, 80 and over; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines	2014
High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines	2014
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:4 Topics: Animals; Bile Ducts; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Diethylnitrosamine; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Hepatic Stellate Cells; Hepatocytes; Humans; Ligation; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred Strains; Phosphorylation; Prognosis; Quinazolines; Rats; Rats, Wistar; Transcriptome	2014
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. International journal of radiation oncology, biology, physics, 2014, Jun-01, Volume: 89, Issue:2 Topics: Adenocarcinoma; Brain Neoplasms; Cranial Irradiation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis	2014
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 84, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines	2014
Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes, 2014, Volume: 63, Issue:6 Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Blood Glucose; Blood Pressure; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Immunohistochemistry; Kidney; Mice; Mice, Inbred NOD; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2014
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. Clinical lung cancer, 2014, Volume: 15, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Italy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases	2014
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung cancer (Amsterdam, Netherlands), 2014, Volume: 85, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors	2014
Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment. American journal of clinical oncology, 2016, Volume: 39, Issue:6 Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Salvage Therapy; Sex Factors; Survival Analysis; Treatment Outcome	2016
EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 85, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Repetitive Sequences, Nucleic Acid; Risk Factors; Treatment Outcome	2014
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis	2014
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor. Journal of clinical pathology, 2015, Volume: 68, Issue:4 Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2015
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung cancer (Amsterdam, Netherlands), 2015, Volume: 88, Issue:1 Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Radiography; Small Cell Lung Carcinoma	2015
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature communications, 2015, Mar-11, Volume: 6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides	2015
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question. Tumori, 2015, Jul-24, Volume: 101, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed	2015
Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer. Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:9 Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Carcinogens; Carcinoma, Squamous Cell; Disease Progression; Down-Regulation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, SCID; Mouth Neoplasms; Neoplasm Transplantation; Quinolones	2015
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2016
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors	2015
Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer. Clinical lung cancer, 2016, Volume: 17, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Survival Rate	2016
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2015, Volume: 18, Issue:6 Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Markov Chains; Models, Economic; Molecular Targeted Therapy; Mutation; Patient Selection; Pemetrexed; Protein Kinase Inhibitors; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Uncertainty; United States	2015
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Academic radiology, 2016, Volume: 23, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Young Adult	2016
Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Clinical lung cancer, 2016, Volume: 17, Issue:2 Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Precision Medicine; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib	2016
Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. European journal of cancer (Oxford, England : 1990), 2016, Volume: 55 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biotransformation; Carcinoma, Non-Small-Cell Lung; Dealkylation; Disease Progression; Disease-Free Survival; Drug Dosage Calculations; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Germany; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Severity of Illness Index	2016
Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors. Oncotarget, 2016, Sep-06, Volume: 7, Issue:36 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Assay; Biphenyl Compounds; Bronchi; Carcinogenesis; Cell Cycle; Cell Proliferation; Cell Survival; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Lignans; Lung Neoplasms; Magnolia; Mice; Molecular Docking Simulation; Nitrosamines; Plant Extracts; RNA, Small Interfering	2016
Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Feb-01, Volume: 23, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Immunological; Cetuximab; Clodronic Acid; Cytokines; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, Synthetic; Humans; Lung Neoplasms; Macrophage Activation; Macrophages, Alveolar; Mice; Mice, Transgenic; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Recombinant Fusion Proteins; Smoking; Uteroglobin	2017
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer. Oncotarget, 2016, Sep-27, Volume: 7, Issue:39 Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases	2016
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung cancer (Amsterdam, Netherlands), 2016, Volume: 100 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Programmed Cell Death 1 Receptor; Quinazolines; Survival Analysis; Tumor Escape	2016
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget, 2016, Dec-20, Volume: 7, Issue:51 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Databases, Factual; Disease Progression; Disease-Free Survival; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Singapore; Time Factors; Treatment Outcome	2016
Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib. Cancer letters, 2017, 03-01, Volume: 388 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Neurotensin; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transfection	2017
[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2017, Feb-23, Volume: 39, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2017
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes. The New Zealand medical journal, 2017, Mar-03, Volume: 130, Issue:1451 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Financing, Government; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Audit; Middle Aged; New Zealand; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2017
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Transplantation, Heterologous	2008
[Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:6 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Salvage Therapy; Treatment Failure	2008
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:3 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking	2009
Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. American journal of respiratory cell and molecular biology, 2009, Volume: 41, Issue:5 Topics: Animals; Carrier Proteins; Collagen; Disease Models, Animal; Disease Progression; Doxycycline; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Lung; Mice; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Fibrosis; Quinazolines; Respiratory Mechanics; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha; Uteroglobin	2009
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed	2009
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome	2010
[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months]. Revue de pneumologie clinique, 2009, Volume: 65, Issue:5 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines	2009
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib. Dermatology online journal, 2009, Nov-15, Volume: 15, Issue:11 Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome	2009
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer. Anticancer research, 2009, Volume: 29, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors	2009
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer, 2010, Mar-01, Volume: 116, Issue:5 Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Korea; Male; Protein Kinase Inhibitors; Quinazolines	2010
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome; Whole-Body Irradiation	2010
Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, May-01, Volume: 16, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome	2010
Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quinazolines; Risk	2010
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland. Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome	2010
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2010, Volume: 31, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Audiometry, Pure-Tone; Disease Progression; Erlotinib Hydrochloride; Female; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Speech Perception; Treatment Outcome; Young Adult	2010
Toxicity manifesting as cosmetic hair alterations during erlotinib treatment. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:1 Topics: Adenocarcinoma; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Hypertrichosis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2011
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Dec-01, Volume: 16, Issue:23 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome	2010
Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Tumor Burden	2011
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC cancer, 2011, Mar-02, Volume: 11 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2011
Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Withholding Treatment	2011
Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer. Technology Evaluation Center Assessment Program. Executive summary, 2011, Volume: 25, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Technology Assessment, Biomedical; Treatment Outcome	2011
[Management of patients with resistance to EGFR-TKI]. Revue de pneumologie clinique, 2011, Volume: 67 Suppl 1 Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Treatment Outcome	2011
Erlotinib-induced rash spares previously irradiated skin. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:8 Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed	2011
Drug-induced effects on erlotinib metabolism. The New England journal of medicine, 2011, Jul-28, Volume: 365, Issue:4 Topics: Adenocarcinoma; Aged; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines	2011
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Oct-01, Volume: 17, Issue:19 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Withholding Treatment	2011
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2 Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth	2011
[Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011, Volume: 14, Issue:10 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Treatment Outcome	2011
Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. World journal of gastroenterology, 2011, Nov-28, Volume: 17, Issue:44 Topics: Animals; Cell Line; Cell Proliferation; Colitis; Colon; Colonic Neoplasms; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid	2011
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. Anticancer research, 2011, Volume: 31, Issue:12 Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome	2011
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome	2012
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation]. No shinkei geka. Neurological surgery, 2012, Volume: 40, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt	2012
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Aug-15, Volume: 18, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors	2012
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies	2012
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management. The Medical journal of Malaysia, 2012, Volume: 67, Issue:2 Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2012
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. Cancer research, 2012, Nov-15, Volume: 72, Issue:22 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors	2012
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Combined Modality Therapy; Crizotinib; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Young Adult	2012
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. Reviews on recent clinical trials, 2013, Volume: 8, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic	2013
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS medicine, 2005, Volume: 2, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured	2005
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome	2005
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Patient Selection; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Time Factors; Vascular Endothelial Growth Factor A	2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-01, Volume: 12, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate; Treatment Outcome	2006
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 56, Issue:1 Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2007
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10 Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome	2007
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines	2007
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2007
Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-20, Volume: 25, Issue:27 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Research Design; Vascular Endothelial Growth Factor A	2007
Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. Lung cancer (Amsterdam, Netherlands), 2008, Volume: 60, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cesarean Section; Disease Progression; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infant, Newborn; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines; Withholding Treatment	2008
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7 Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2008
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate	2008
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4 Topics: Adenocarcinoma; Aged; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Tomography Scanners, X-Ray Computed; Treatment Failure	2008